

Background. Community-acquired (CA) UTI caused by ESBL-producing pathogens pose challenges related to initial antibiotic (AB) selection. Better characterization of AB susceptibilities in CA ESBL infections may improve empiric drug selection for outpatient therapy. The objectives of this study were to describe AB susceptibilities of isolates in CA ESBL UTI and provide recommendations for appropriate treatment at our institution.

Methods. Adult patients with CA ESBL UTI (cystitis) from 2009 through 2013 were retrospectively matched 1:1 with a control group of non-ESBL CA UTI based on age within 5 years, gender, and organism. The primary outcome in this phase of the study was description of AB susceptibilities in CA ESBL UTI vs. controls. Secondary outcomes were comparison of appropriate initial AB therapy (defined as concordance of initial AB with in vitro susceptibilities) and development of recommendations for initial antibiotics for CA UTI.

Results. Eighty-five patients were matched into each of the ESBL and non-ESBL CA UTI groups. *E. coli* was the pathogen in 94% of ESBL UTIs and 96% of controls. Patients with ESBL UTI most often received ceftriaxone or oral β -lactam (BL, 31%), fluoroquinolone (FQ, 27%), trimethoprim/sulfamethoxazole (TMP/SMX, 14%), or nitrofurantoin (NF, 14%); controls were similar. Besides non-carbapenem BLs, ESBL producers were significantly more resistant to FQs (78% resistant), NF (16%), TMP/SMX (60%), gentamicin (33%), and doxycycline (78%) vs. controls ($P < 0.01$ for each). Ertapenem and amikacin had 100% and 96% susceptibility, respectively. Initial AB were discordant in 64% of ESBL UTI vs. 14% of controls (OR 11.0, 95% CI 5.0–24.3; $P < 0.0001$). FQs and TMP/SMX were discordant in 83% and 42% of ESBL UTI, respectively, while NF was concordant in 100% of patients with ESBL UTI and 89% of controls.

Conclusion. Patients with CA ESBL UTI were significantly more likely to receive inappropriate initial AB therapy. Although ESBL-producing strains were resistant to multiple AB classes, NF retained activity against 84% of ESBL isolates and was associated with appropriateness of initial therapy in 100% of patients with ESBL UTI. Nitrofurantoin is an appropriate oral option for treatment of CA UTI, even in patients with ESBL infection.

Disclosures. D. N. Fish, Merck & Co.: Grant Investigator, Research grant M. Barron, Merck & Co.: Grant Investigator, Research grant

1138. Prevalence and Accuracy of Screening Test of Asymptomatic Bacteriuria During Pregnancy in Siriraj Hospital

Jintana Srisompong, MD¹; Suraiya Rahman, BSN²; Kusol Russameecharoen, MD²; Sasima Tongyai, PhD³; Chakkramong Seenama,⁴ and Pornpan Koomanachai, MD⁵; ¹Medicine, Mahidol University, Bangkok, Thailand, ²Obstetric and Gynecology, Siriraj Hospital, Bangkok, Thailand, ³Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁴Medicine, Siriraj hospital, Bangkok, Thailand, ⁵Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Session: 143. Clinical: UTI

Friday, October 6, 2017: 12:30 PM

Background. The early detection and treatment asymptomatic bacteriuria (ASB) during pregnancy prevents maternal and fetal complication. Thus the American College of OB-GYN recommends urine culture should be obtained at the first prenatal visit and the U.S. Preventive Services Task Force obtains urine culture during 12–16 weeks of gestation. The new antenatal care (ANC) model of Thai Ministry of Public Health uses screening at first ANC by urine dipstick. However, neither research nor routine ASB screen in Siriraj Hospital because there was low prevalence and all pregnancy were screened by the obstetricians.

Methods. Prospective cohort study was performed at the ANC clinic, OB-GYN department, Siriraj Hospital. Pregnancies of first antenatal care visit during January to December 2015 were enrolled. Urine culture (UC), Urine dipstick for nitrite (UDN), and Urine dipstick for leukocyte esterase (UDL), were performed. Subjects' baseline characteristics until birth delivery were collected.

Results. Total 702 subjects were enrolled; median age, 28 yrs (range 16–45) and body mass index, 24.1 (range 14.0–44.3). The ASB prevalence was 2.3% (16 from 702) without significant difference between first, second, and third trimester, $P = 0.185$. The most common organism was *E. coli*. Factors related to ASB were heart disease, $P < 0.001$ and having sexual intercourse during pregnancy, $P = 0.005$. The sensitivity and specificity of UDN and UDL were 37.5% and 99.0% and 56.3% and 55.7%, respectively. Positive predictive value and negative predictive value of UDN and UDL were 46.2% and 2.9% and 98.5% and 98.2%, respectively. No abnormal maternal and fetal outcomes were reported.

Conclusion. According to very low prevalence of ASB in Siriraj hospital, routine urine culture may be unnecessary for all antenatal pregnancy. However, heart disease and sexual intercourse during pregnancy should be considered for screening and treatment. However, further evaluation of outcome, i.e. UTI, maternal and fetal complication of non-screening for ASB should be studied.

Disclosures. All authors: No reported disclosures.

1139. Epidemiology, Microbiology and Outcomes of Catheter-Associated Urinary Tract Infection and Complicated Urinary Tract Infection in the USA

Sanjay Merchant, PhD¹; Eric M Sarpong, PhD²; Glenn Magee, MBA³; Nancy Lapointe, PharmD, MHS⁴; Jake Gundrum, MS⁵ and Marya Zilberberg, MD,

MPH⁶; ¹Merck & Co., Inc., Kenilworth, NJ, ²CORE, Merck & Co. Inc., Kenilworth, NJ, ³Premier Research Services, Premier, Inc., Charlotte, NC, ⁴Applied Research, Premier Research Services, Premier, Inc., CHARLOTTE, North Carolina, ⁵Premier Research Services, Premier, Inc., CHARLOTTE, North Carolina, ⁶EviMed Research Group, LLC, Goshen, Massachusetts

Session: 143. Clinical: UTI

Friday, October 6, 2017: 12:30 PM

Background. An estimated 93,300 cases of healthcare-associated urinary tract infection (UTI) were recorded in US acute care hospitals in 2011. Many are classified as catheter-associated UTI (CAUTI) or complicated UTI (cUTI). Although CAUTI and cUTI share some commonalities, strategies differ for their prevention and treatment. We examined the epidemiology, microbiology and outcome of patients with CAUTI and cUTI in a large multicenter US database.

Methods. This was a retrospective cohort study using the 2013–2015 Premier Healthcare Database. ICD-9-CM codes were used to identify hospitalized adults (≥ 18 years) with CAUTI or cUTI. The demographics, clinical characteristics, microbiology, and hospital outcomes of all identified patients were compared. Differences between groups were examined using χ^2 test for categorical variables and Student's t-test for continuous variables. Statistical significance was set at $P \leq 0.05$.

Results. Of 120,332 identified patients, 50,034 (41.6%) had CAUTI (87.0% present on admission [POA]) and the remainder had cUTI [95.3% POA]. Patients with CAUTI were older (71.3 ± 16.1 vs. 56.3 ± 19.5 years) and more likely to be male (62.5% vs. 30.6%) and white (71.6% vs. 66.7%) (all $P < 0.001$). They also had greater comorbidity burden (Charlson Comorbidity Index of 2.8 ± 2.4 vs. 1.7 ± 2.2) and a higher ICU care rate (23.2% vs. 17.8%) than cUTI patients (all $P < 0.001$). Although *Escherichia coli* was the most common pathogen in both (69.8% cUTI vs. 39.5% CAUTI), *Pseudomonas aeruginosa* accounted for one quarter of all CAUTIs and only 5.0% of cUTIs. Compared with cUTI, CAUTI carried a >2 -fold increase in unadjusted mortality (3.6% vs. 1.6%) and a higher rate of 30-day readmission (3.9% vs. 2.5%) (all $P < 0.001$). Additionally, CAUTI was associated with a greater unadjusted ICU length of stay (LOS, 6.0 ± 8.8 vs. 5.5 ± 5.5 days), hospital LOS (8.4 ± 12.9 vs. 5.5 ± 6.4 days) and cost (\$16,871+\$29,513 vs. \$11,915 ± \$19,657) (all $P < 0.001$).

Conclusion. The volume of CAUTI and cUTI hospitalizations in the US is high, and a majority of infections were present on admission. CAUTI is associated with greater mortality and resource use than cUTI. The high rate of *P. aeruginosa* portends a greater potential for antimicrobial resistance in CAUTI, which may require different prevention and treatment approaches from cUTI.

Disclosures. S. Merchant, 1Merck & Co., Inc.: Employee and Shareholder, Salary E. M. Sarpong, Merck & Co., Inc.: Employee and Shareholder, Salary M. Zilberberg, EviMed Research Group, LLC.; Universtiy of Massachusetts: Shareholder, Research grant

1140. Significance of Prior Culture History for Predicting Urinary Tract Infection Caused by Multi-drug Resistant Enterobacteriaceae

Jefferson Bohan, PharmD, BCPS¹; Richard Remington, MS² and Karl Madaras-Kelly, PharmD, MPH^{1,3}; ¹Vet. Med. Ctr., Boise, Idaho, ²VA Med. Ctr. and Quantified Inc., Boise, Idaho, ³Coll. of Pharmacy, Idaho State University, Meridian, Idaho

Session: 143. Clinical: UTI

Friday, October 6, 2017: 12:30 PM

Background. Extended-spectrum β -lactamase (ESBL) -producing *E. coli*, *Klebsiella* spp., and *Proteus* spp. (EKP), that cause urinary tract infections (UTI) are resistant to first-line therapies (e.g., ceftriaxone). Prediction of UTI caused by ESBL-producing organisms is important for selection of empirical therapy. The objective was to develop a prediction model to identify UTI caused by ceftriaxone (CRO)-resistant EKP and compare the model to other commonly cited predictive models (Tumbarello M et al. AAC Jul 2011; Johnson SW et al. ICHE Apr 2013).

Methods. A single-center, matched, case-control of Veterans Affairs (VA) outpatients with a positive ($\geq 10^4$ CFU/mL) urine culture was conducted. Patients were excluded if they had no UTI diagnosis or documented symptoms, age < 18 , transfer from another hospital, or a significant urine culture result. Cases were defined as any patient with a CRO-resistant EKP; controls were matched 4:1 to cases based on incident density (≤ 30 days) by random selection. Logistic regression and receiver operator curves were used to develop and assess models.

Results. One hundred subjects were included in the analysis. Demographics were similar except for age [Case 73.5 years (13.7); Control 64.5 years (15.2); $P = 0.02$] and history of CRO-resistant EKP in last 6 months (Case 40%; Control 0%; $P < 0.01$). Predictor variables in the final model (Likelihood Ratio 44.2, $P < 0.01$) included history of CRO-resistant EKP in last 6 months (131.5, 12.2–18308.0), cephalosporin use in past 60 days (12.7, 1.9–94.5), residence in a skilled nursing or assisted living facility (8.0, 1.6–40.5), and hospitalization in last 6 months (OR 3.0, 95% CI 0.7–12.5). In the VA population, the other models predicted significantly although less accurately (Figure 1).

Conclusion. Prior cephalosporin use, hospitalization, and residence were important predictors of UTI caused by CRO-resistant EKP; however, prior history of CRO-resistant EKP was the most important predictor. A Model that included prior culture results predicted CRO-resistant UTIs better than other commonly cited models that do not contain prior ESBL history. Prior culture data should be considered when selecting empirical antibiotics for UTI. Validation in a larger cohort is warranted.